CD19 and acute lymphoblastic leukemia: For instance, reinfusion of CD22 CAR-T cells displayed substantial clinical benefit in patients with r/r B-cell acute lymphoblastic leukemia (B-ALL) who had previously relapsed due to CD19 antigen loss after CD19 CAR-T therapy (148).